A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.

Maria de Fátima Pinela da Silva Mousinho de Palhares FalcãoErica ViegasInes CarmoJoana SoaresMargarida FalcaoMariana SolanoPatricia CavacoDina MendesJoão RijoPedro PovoaAntonio Pais MartinsEduarda CarmoKamal MansinhoCandida FonsecaLuis CamposAntónio CarvalhoAna MircoHelena FarinhaIsabel AldirJosé Correia

Published in: European journal of hospital pharmacy : science and practice (2021)

Real-world data are crucial to further establish the safety profile for REM. HCQ is no longer recommended for the treatment of COVID-19.

Keyphrases

adverse drug
electronic health record
coronavirus disease
sars cov
combination therapy
big data
data analysis
drug induced
replacement therapy